Scinai Immunotherapeutics (SCNI) vs Silexion Therapeutics (SLXN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Silexion Therapeutics is the larger company by market cap ($3.1 million vs $1.6 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCNI | SLXN |
|---|---|---|
| Share price | $1.18 | $0.2146 |
| Market cap | $1.60M | $3.11M |
| 1-day change | -2.48% | -8.64% |
| P/E ratio (TTM) | 0.04 | — |
| EPS (TTM) | $28.07 | $-27.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.65 | $40.70 |
| 52-week low | $1.06 | $0.2079 |
| Distance from 52-week high | -92.46% | -99.47% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2229.92% |
| Average volume | 1.10M | 9.90M |
| Shares outstanding | 1.35M | 14.47M |
| Employees | 45 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
SCNI vs SLXN FAQ
Which is bigger, Scinai Immunotherapeutics or Silexion Therapeutics?
Silexion Therapeutics (SLXN) is larger, with a market capitalization of $3.11M compared with $1.60M for Scinai Immunotherapeutics (SCNI).
Are Scinai Immunotherapeutics and Silexion Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.